These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 20141673)

  • 1. Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia.
    Richardson PG; Laubach JP; Schlossman RL; Mitsiades C; Anderson K
    J Natl Compr Canc Netw; 2010 Feb; 8 Suppl 1():S4-S12. PubMed ID: 20141673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of multiple myeloma: thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathy.
    Koeppen S
    Oncol Res Treat; 2014; 37(9):506-13. PubMed ID: 25231692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
    Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
    Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma.
    El-Cheikh J; Stoppa AM; Bouabdallah R; de Lavallade H; Coso D; de Collela JM; Auran-Schleinitz T; Gastaut JA; Blaise D; Mohty M
    Clin Lymphoma Myeloma; 2008 Jun; 8(3):146-52. PubMed ID: 18650177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues.
    Delforge M; Bladé J; Dimopoulos MA; Facon T; Kropff M; Ludwig H; Palumbo A; Van Damme P; San-Miguel JF; Sonneveld P
    Lancet Oncol; 2010 Nov; 11(11):1086-95. PubMed ID: 20932799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.
    Mohty B; El-Cheikh J; Yakoub-Agha I; Moreau P; Harousseau JL; Mohty M
    Haematologica; 2010 Feb; 95(2):311-9. PubMed ID: 20139393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of treatment-related adverse events in patients with multiple myeloma.
    Mateos MV
    Cancer Treat Rev; 2010 May; 36 Suppl 2():S24-32. PubMed ID: 20472185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of treatment-emergent peripheral neuropathy in multiple myeloma.
    Richardson PG; Delforge M; Beksac M; Wen P; Jongen JL; Sezer O; Terpos E; Munshi N; Palumbo A; Rajkumar SV; Harousseau JL; Moreau P; Avet-Loiseau H; Lee JH; Cavo M; Merlini G; Voorhees P; Chng WJ; Mazumder A; Usmani S; Einsele H; Comenzo R; Orlowski R; Vesole D; Lahuerta JJ; Niesvizky R; Siegel D; Mateos MV; Dimopoulos M; Lonial S; Jagannath S; Bladé J; Miguel JS; Morgan G; Anderson KC; Durie BG; Sonneveld P
    Leukemia; 2012 Apr; 26(4):595-608. PubMed ID: 22193964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib-induced peripheral neuropathy in patients with multiple myeloma.
    Berkowitz A; Walker S
    Clin J Oncol Nurs; 2012 Feb; 16(1):86-9. PubMed ID: 22297012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.
    Martin TG
    Oncology (Williston Park); 2013 Dec; 27 Suppl 3():4-10. PubMed ID: 25184230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy.
    Chaudhry V; Cornblath DR; Polydefkis M; Ferguson A; Borrello I
    J Peripher Nerv Syst; 2008 Dec; 13(4):275-82. PubMed ID: 19192067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients.
    Corso A; Mangiacavalli S; Varettoni M; Pascutto C; Zappasodi P; Lazzarino M
    Leuk Res; 2010 Apr; 34(4):471-4. PubMed ID: 19674790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple myeloma.
    Crawford CL
    N Engl J Med; 2005 Feb; 352(8):840-1; author reply 840-1. PubMed ID: 15736295
    [No Abstract]   [Full Text] [Related]  

  • 14. Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.
    Cavaletti G; Jakubowiak AJ
    Leuk Lymphoma; 2010 Jul; 51(7):1178-87. PubMed ID: 20497001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
    Broyl A; Corthals SL; Jongen JL; van der Holt B; Kuiper R; de Knegt Y; van Duin M; el Jarari L; Bertsch U; Lokhorst HM; Durie BG; Goldschmidt H; Sonneveld P
    Lancet Oncol; 2010 Nov; 11(11):1057-65. PubMed ID: 20864405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of bortezomib induced peripheral neuropathy in multiple myeloma by the reduced Total Neuropathy Score.
    Zaroulis CK; Chairopoulos K; Sachanas SP; Maltezas D; Tzenou T; Pessach I; Koulieris E; Koutra E; Kilindireas K; Pangalis GA; Kyrtsonis MC
    Leuk Lymphoma; 2014 Oct; 55(10):2277-83. PubMed ID: 24552516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study.
    Tacchetti P; Terragna C; Galli M; Zamagni E; Petrucci MT; Pezzi A; Montefusco V; Martello M; Tosi P; Baldini L; Peccatori J; Ruggieri M; Pantani L; Lazzaro A; Elice F; Rocchi S; Gozzetti A; Cavaletti G; Palumbo A; Cavo M
    Am J Hematol; 2014 Dec; 89(12):1085-91. PubMed ID: 25159313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib-induced severe autonomic neuropathy.
    Stratogianni A; Tosch M; Schlemmer H; Weis J; Katona I; Isenmann S; Haensch CA
    Clin Auton Res; 2012 Aug; 22(4):199-202. PubMed ID: 22532274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. General aspects and mechanisms of peripheral neuropathy associated with bortezomib in patients with newly diagnosed multiple myeloma.
    Broyl A; Jongen JL; Sonneveld P
    Semin Hematol; 2012 Jul; 49(3):249-57. PubMed ID: 22726548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical assessment of bortezomib for multiple myeloma in comparison with thalidomide.
    Satoh M; Oguro R; Yamanaka C; Takada K; Matsuura Y; Akiba T; Aotsuka N; Tani Y; Wakita H
    J Pharm Pharm Sci; 2011; 14(1):78-89. PubMed ID: 21501555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.